FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2910362376> ?p ?o ?g. }

• W2910362376 endingPage "112" @default.
• W2910362376 startingPage "108" @default.
• W2910362376 abstract "Because gestational trophoblastic disease is rare, little evidence is available from randomized controlled trials on optimal treatment and follow-up. Treatment protocols vary within Europe, and even between different centers within countries. One of the goals of the European Organization for Treatment of Trophoblastic Diseases (EOTTD) is to harmonize treatment in Europe. To provide a basis for international standardization of definitions, treatment and follow-up protocols in gestational trophoblastic disease, we evaluated differences and similarities between protocols in EOTTD countries.Members from each EOTTD country were asked to complete an online structured questionnaire comprising multiple-choice and multiple-answer questions. The following themes were discussed: incidence of gestational trophoblastic disease and gestational trophoblastic neoplasia, definitions, guidelines, classification system, treatment, recurrence, and follow-up.Forty-four respondents from 17 countries participated in this study. Guidelines were present in 80% of the countries and the FIGO (Fédération Internationale de Gynécologie et d'Obstétrique) staging and risk classification was often used to estimate risks. Agreement about when to start chemotherapy for post-molar gestational trophoblastic neoplasia was present among 66% of the respondents. Preferred first-line treatments in low- and high-risk gestational trophoblastic neoplasia were methotrexate (81%) and EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) (93%), respectively. The definition of human chorionic gonadotropin normalization after hydatidiform mole evacuation was two consecutive normal values for nine countries. The FIGO definition of post-molar gestational trophoblastic neoplasia based on human chorionic gonadotropin plateau or rise was agreed on by 69% of respondents, and only 69% and 74% defined low-risk and high-risk disease, respectively, using FIGO criteria. There were major differences in definitions of recurrence, chemotherapy resistance and follow-up protocols among countries, despite EOTTD consensus statements.This questionnaire provides a good overview of current clinical practices in different countries. Based on the survey results, it is clear that there are several gestationaltrophoblastic disease-related topics that need urgent attention within the EOTTD community to create more uniformity and to aid the development of uniform guidelines in Europe." @default.
• W2910362376 created "2019-01-25" @default.
• W2910362376 creator A5001291478 @default.
• W2910362376 creator A5004064474 @default.
• W2910362376 creator A5006320956 @default.
• W2910362376 creator A5017968529 @default.
• W2910362376 creator A5030012957 @default.
• W2910362376 creator A5039031691 @default.
• W2910362376 creator A5044960311 @default.
• W2910362376 creator A5077650743 @default.
• W2910362376 date "2019-01-01" @default.
• W2910362376 modified "2023-10-18" @default.
• W2910362376 title "Is there uniformity in definitions and treatment of gestational trophoblastic disease in Europe?" @default.
• W2910362376 cites W1833898476 @default.
• W2910362376 cites W2010443570 @default.
• W2910362376 cites W2017645415 @default.
• W2910362376 cites W2022787659 @default.
• W2910362376 cites W2023273774 @default.
• W2910362376 cites W2028063483 @default.
• W2910362376 cites W2038477676 @default.
• W2910362376 cites W2079569621 @default.
• W2910362376 cites W2080355111 @default.
• W2910362376 cites W2097338242 @default.
• W2910362376 cites W2162198154 @default.
• W2910362376 cites W2170134875 @default.
• W2910362376 cites W2174345508 @default.
• W2910362376 cites W2289378191 @default.
• W2910362376 doi "https://doi.org/10.1136/ijgc-2018-000028" @default.
• W2910362376 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30640691" @default.
• W2910362376 hasPublicationYear "2019" @default.
• W2910362376 type Work @default.
• W2910362376 sameAs 2910362376 @default.
• W2910362376 citedByCount "12" @default.
• W2910362376 countsByYear W29103623762020 @default.
• W2910362376 countsByYear W29103623762021 @default.
• W2910362376 countsByYear W29103623762022 @default.
• W2910362376 countsByYear W29103623762023 @default.
• W2910362376 crossrefType "journal-article" @default.
• W2910362376 hasAuthorship W2910362376A5001291478 @default.
• W2910362376 hasAuthorship W2910362376A5004064474 @default.
• W2910362376 hasAuthorship W2910362376A5006320956 @default.
• W2910362376 hasAuthorship W2910362376A5017968529 @default.
• W2910362376 hasAuthorship W2910362376A5030012957 @default.
• W2910362376 hasAuthorship W2910362376A5039031691 @default.
• W2910362376 hasAuthorship W2910362376A5044960311 @default.
• W2910362376 hasAuthorship W2910362376A5077650743 @default.
• W2910362376 hasConcept C126322002 @default.
• W2910362376 hasConcept C131872663 @default.
• W2910362376 hasConcept C2775948956 @default.
• W2910362376 hasConcept C2776694085 @default.
• W2910362376 hasConcept C2778119113 @default.
• W2910362376 hasConcept C2778165768 @default.
• W2910362376 hasConcept C2778383414 @default.
• W2910362376 hasConcept C2779234561 @default.
• W2910362376 hasConcept C2781059491 @default.
• W2910362376 hasConcept C2909081632 @default.
• W2910362376 hasConcept C2909593222 @default.
• W2910362376 hasConcept C29456083 @default.
• W2910362376 hasConcept C46973012 @default.
• W2910362376 hasConcept C54355233 @default.
• W2910362376 hasConcept C71315377 @default.
• W2910362376 hasConcept C71924100 @default.
• W2910362376 hasConcept C86803240 @default.
• W2910362376 hasConceptScore W2910362376C126322002 @default.
• W2910362376 hasConceptScore W2910362376C131872663 @default.
• W2910362376 hasConceptScore W2910362376C2775948956 @default.
• W2910362376 hasConceptScore W2910362376C2776694085 @default.
• W2910362376 hasConceptScore W2910362376C2778119113 @default.
• W2910362376 hasConceptScore W2910362376C2778165768 @default.
• W2910362376 hasConceptScore W2910362376C2778383414 @default.
• W2910362376 hasConceptScore W2910362376C2779234561 @default.
• W2910362376 hasConceptScore W2910362376C2781059491 @default.
• W2910362376 hasConceptScore W2910362376C2909081632 @default.
• W2910362376 hasConceptScore W2910362376C2909593222 @default.
• W2910362376 hasConceptScore W2910362376C29456083 @default.
• W2910362376 hasConceptScore W2910362376C46973012 @default.
• W2910362376 hasConceptScore W2910362376C54355233 @default.
• W2910362376 hasConceptScore W2910362376C71315377 @default.
• W2910362376 hasConceptScore W2910362376C71924100 @default.
• W2910362376 hasConceptScore W2910362376C86803240 @default.
• W2910362376 hasIssue "1" @default.
• W2910362376 hasLocation W29103623761 @default.
• W2910362376 hasLocation W29103623762 @default.
• W2910362376 hasOpenAccess W2910362376 @default.
• W2910362376 hasPrimaryLocation W29103623761 @default.
• W2910362376 hasRelatedWork W2058198830 @default.
• W2910362376 hasRelatedWork W2065395099 @default.
• W2910362376 hasRelatedWork W2770657147 @default.
• W2910362376 hasRelatedWork W2910362376 @default.
• W2910362376 hasRelatedWork W2931441064 @default.
• W2910362376 hasRelatedWork W2986605649 @default.
• W2910362376 hasRelatedWork W3093686791 @default.
• W2910362376 hasRelatedWork W3204828993 @default.
• W2910362376 hasRelatedWork W4245803820 @default.
• W2910362376 hasRelatedWork W94765172 @default.
• W2910362376 hasVolume "29" @default.
• W2910362376 isParatext "false" @default.
• W2910362376 isRetracted "false" @default.

• next